Deucravacitinib

The safety and efficacy of deucravacitinib, an investigational agent, have not been established.

About the TYK2 Immune Pathway

Tyrosine kinase 2 (TYK2) is an intracellular enzyme that mediates select immune and inflammatory pathways.1-7

TYK2 protein
Cytokine receptor
Cytokine
T cell

About Deucravacitinib

Deucravacitinib is a first-in-class, oral, selective TYK2 inhibitor with a unique mechanism of action.

Deucravacitinib was designed to selectively target TYK2, thereby inhibiting signaling of interleukin (IL)-12, IL-23 and Type 1 interferon (IFN), key cytokines involved in the pathogenesis of immune-mediated diseases.

What Sets Deucravacitinib Apart

At therapeutic doses, deucravacitinib has not been shown to inhibit pathways that are mediated only by JAK1, 2, 3, including those involved in hematopoiesis, myelopoiesis and lipid metabolism.

Deucravacitinib has the potential to become an important treatment option for patients who require systemic therapy for their moderate to severe plaque psoriasis, with the convenience of a once-daily oral dose.

Deucravacitinib Clinical Trials

Deucravacitinib is the first and only TYK2 inhibitor in clinical studies across multiple immune-mediated diseases.8-14

<table>
<thead>
<tr>
<th>Disease Area</th>
<th>Phase 2</th>
<th>Phase 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Psoriatic arthritis</td>
<td>✔</td>
<td>✔</td>
</tr>
<tr>
<td>Crohn's disease</td>
<td>✔</td>
<td>✔</td>
</tr>
<tr>
<td>Ulcerative colitis</td>
<td>✔</td>
<td>✔</td>
</tr>
<tr>
<td>Lupus</td>
<td>✔</td>
<td>✔</td>
</tr>
<tr>
<td>Psoriasis</td>
<td>✔</td>
<td>✔</td>
</tr>
</tbody>
</table>

Deucravacitinib is an investigational treatment option and is not approved for use by a regulatory authority in any country.

Bristol Myers Squibb is committed to pursuing pathbreaking science to deliver meaningful solutions that address unmet needs and improve the lives of people living with psoriasis and other immune-mediated diseases.

Bristol Myers Squibb Clinical Trials

- Psoriatic arthritis
- Crohn's disease
- Ulcerative colitis
- Lupus
- Psoriasis

Bristol Myers Squibb is an investigational treatment option and is not approved for use by a regulatory authority in any country.

References: